An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

Condition:   Tuberculosis Interventions:   Drug: GSK3036656;   Drug: RIFAFOUR e-275 Sponsor:   GlaxoSmithKline Not yet recruiting

Source: ClinicalTrials.gov - June 15, 2018 Category: Research Source Type: clinical trials